Two-by-two factorial comparison of high-bolus-dose tirofiban followed by standard infusion versus abciximab and sirolimus-eluting versus bare-metal stent implantation in patients with acute myocardial infarction. Design and rationale for the MULTI-STRATEGY trial

American Heart Journal

Volumn 154, Issue 1, 2007, Pages 39-45

  Valgimigli, Marco ^a,b   Bolognese, Leonardo ^c   Anselmi, Maurizio ^d   Campo, Gianluca ^a   Rodriguez, Alfredo E ^e   de Cesare, Nicoletta ^f   Cohen, David J ^g   Sheiban, Imad ^h   Colangelo, Salvatore ⁱ   Pasquetto, Giampaolo ^j   Hamon, Martial ^k   Vranckx, Pascal ^l   Ferrario, Maurizio ^m   Prati, Francesco ⁿ   Agostoni, Pierfrancesco ^o   Malagutti, Patrizia ^b   Arcozzi, Chiara ^b   Parrinello, Giovanni ^p   Vassanelli, Corrado ^d   Ferrari, Roberto ^a,b   Percoco, Gianfranco ^a   more..

^a UNIVERSITY OF FERRARA   (Italy)

^b IRCCS   (Italy)

^c IRCCS POLICLINICO SAN DONATO   (Italy)

^d UNIVERSITY OF VERONA   (Italy)

^e Sanatorio Otamendi y Miroli   (Argentina)

^f Policlinico San Marco   (Italy)

^g SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^h UNIVERSITY OF TURIN   (Italy)

ⁱ MOLINETTE HOSPITAL   (Italy)

^j Civic Hospital   (Italy)

^k CAEN UNIVERSITY HOSPITAL   (France)

^l VIRGA JESSE HOSPITAL   (Belgium)

^m FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

ⁿ CATHOLIC UNIVERSITY   (Italy)

^o MIDDELHEIM HOSPITAL   (Belgium)

^p UNIVERSITY OF BRESCIA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN; RAPAMYCIN; TIROFIBAN;

ACUTE HEART INFARCTION; ADULT; ARTICLE; BLEEDING; BOLUS INJECTION; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY STENT; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG ELUTING STENT; DRUG MEGADOSE; DRUG SAFETY; FACTORIAL DESIGN; FEMALE; FLOW RATE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REPERFUSION; ST SEGMENT ELEVATION;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS, PHASE III; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INFUSIONS, INTRAVENOUS; METALS; MYOCARDIAL INFARCTION; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; SIROLIMUS; STENTS; TYROSINE;

EID: 34250647924     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2007.03.023     Document Type: Article

References (26)

1. Antman E.M., Anbe D.T., Armstrong P.W., et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 110 (2004) e82-e292
2. Topol E.J., Neumann F.J., and Montalescot G. A preferred reperfusion strategy for acute myocardial infarction. J Am Coll Cardiol 42 (2003) 1886-1889
3. Van de Werf F. Drug-eluting stents in acute myocardial infarction. N Engl J Med 355 (2006) 1169-1170
4. Zhu M.M., Feit A., Chadow H., et al. Primary stent implantation compared with primary balloon angioplasty for acute myocardial infarction: a meta-analysis of randomized clinical trials. Am J Cardiol 88 (2001) 297-301
5. Nordmann A.J., Bucher H., Hengstler P., et al. Primary stenting versus primary balloon angioplasty for treating acute myocardial infarction. Cochrane Database Syst Rev (2005) CD005313
6. Valgimigli M., Percoco G., Malagutti P., et al. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA 293 (2005) 2109-2117
7. Spaulding C., Henry P., Teiger E., et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 355 (2006) 1093-1104
8. Menichelli M. Randomised trial of sirolimus eluting stent vs. bare metal stent in acute myocardial infarction (SESAMI). Presented at 2006 Euro-PCR, 16th May 2006, Paris (2006)
9. Laarman G.J., Suttorp M.J., Dirksen M.T., et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med 355 (2006) 1105-1113
10. Valgimigli M., Percoco G., and Bolognese L. Drug-eluting stents in primary PCI. N Engl J Med 355 (2006) 2484 [author reply 2484-6]
11. De Luca G., Suryapranata H., Stone G.W., et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA 293 (2005) 1759-1765
12. Topol E.J., Moliterno D.J., Herrmann H.C., et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 344 (2001) 1888-1894
13. Schneider D.J., Herrmann H.C., Lakkis N., et al. Increased concentrations of tirofiban in blood and their correlation with inhibition of platelet aggregation after greater bolus doses of tirofiban. Am J Cardiol 91 (2003) 334-336
14. Valgimigli M., Percoco G., Barbieri D., et al. The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE Trial. J Am Coll Cardiol 44 (2004) 14-19
15. Danzi G.B., Sesana M., Capuano C., et al. Comparison in patients having primary coronary angioplasty of abciximab versus tirofiban on recovery of left ventricular function. Am J Cardiol 94 (2004) 35-39
16. Bolognese L., Falsini G., Liistro F., et al. Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trial. J Am Coll Cardiol 47 (2006) 522-528
17. Spertus J.A., Kettelkamp R., Vance C., et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 113 (2006) 2803-2809
18. Piaggio G., Elbourne D.R., Altman D.G., et al. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA 295 (2006) 1152-1160
19. van't Hof A.W., Liem A., de Boer M.J., et al. Clinical value of 12-lead electrocardiogram after successful reperfusion therapy for acute myocardial infarction. Zwolle Myocardial infarction Study Group. Lancet 350 (1997) 615-619
20. Schroder R. Prognostic impact of early ST-segment resolution in acute ST-elevation myocardial infarction. Circulation 110 (2004) e506-e510
21. De Luca G., van't Hof A.W., de Boer M.J., et al. Time-to-treatment significantly affects the extent of ST-segment resolution and myocardial blush in patients with acute myocardial infarction treated by primary angioplasty. Eur Heart J 25 (2004) 1009-1013
22. Antoniucci D., Rodriguez A., Hempel A., et al. A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. J Am Coll Cardiol 42 (2003) 1879-1885
23. Godicke J., Flather M., Noc M., et al. Early versus periprocedural administration of abciximab for primary angioplasty: a pooled analysis of 6 studies. Am Heart J 150 (2005) 1015
24. Campo G., Valgimigli M., Gemmati D., et al. Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: insights into the STRATEGY Study. J Am Coll Cardiol 48 (2006) 2178-2185
25. Stone G.W., Webb J., Cox D.A., et al. Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation myocardial infarction: a randomized controlled trial. JAMA 293 (2005) 1063-1072
26. McAlister F.A., Straus S.E., Sackett D.L., et al. Analysis and reporting of factorial trials: a systematic review. JAMA 289 (2003) 2545-2553